ALCOR LIFE EXTENSION FOUNDATION

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1972

Legal Domicile

Principal Officer

MARJI KLIMA

Phone

4809051906

Tax Period

2023-01-01 to 2023-12-31

ALCOR LIFE EXTENSION FOUNDATION, founded in 1972, is a community nonprofit in the Science & Technology sector that reported $5.7M in total revenue in fiscal year 2023. Revenue surged 51% from the prior year, signaling strong growth momentum. The organization ran a surplus of $1.8M, a strong 32% operating margin.

Mission

THE PRESERVATION OF INDIVIDUAL LIVES, TO BE SOUGHT THROUGH THE FOLLOWING PRIORITIZED LIST OF FUNDAMENTALS: MAINTAIN THE CURRENT PATIENTS IN BIOSTASIS, PLACE CURRENT AND FUTURE MEMBERS INTO BIOSTASIS (WHEN AND IF NEEDED), EVENTUALLY RESTORE HEALTH TO ALL PATIENTS IN... THE PRESERVATION OF INDIVIDUAL LIVES, TO BE SOUGHT THROUGH THE FOLLOWING PRIORITIZED LIST OF FUNDAMENTALS: MAINTAIN THE CURRENT PATIENTS IN BIOSTASIS, PLACE CURRENT AND FUTURE MEMBERS INTO BIOSTASIS (WHEN AND IF NEEDED), EVENTUALLY RESTORE HEALTH TO ALL PATIENTS IN ALCOR'S CARE, FUND RESEARCH INTO DEVELOPING MORE COST EFFECTIVE AND RELIABLE MEANS FOR THE ABOVE AND PROVIDE PUBLIC EDUCATION AS A MEANS OF FOSTERING GROWTH TO SUPPORT THE GOALS OF THE ABOVE.FORM 990, PART V, LINE 2A:ALCOR LIFE EXTENSION FOUNDATION HAS NO EMPLOYEES. THE ORGANIZATION LEASES EMPLOYEES FROM EMPLOYERS RESOURCE ON A DIRECT REIMBURSEMENT BASIS.

Program Service Accomplishments

Program 1

Expenses: $2,398,479 Revenue: $2,089,486

TO PROMOTE, FOSTER AND CONDUCT BASIC AND APPLIED RESEARCH IN ALL AREAS OF THE LIFE EXTENSION SCIENCES INCLUDING, BUT NOT LIMITED TO, CRYONICS, CRYOBIOLOGY, GERONTOLOGY, MOLECULAR ENGINEERING AND CELL REPAIR TECHNOLOGY.TO ENGAGE IN THE APPLICATION OF WHOLE-BODY CRYONIC SUSPENSION, NEUROPRESERVATION AND OTHER POSTMORTEM AND BIOPRESERVATION TECHNIQUES AND TO PROVIDE THESE SERVICES TO THE GENERAL PUBLIC.TO EDUCATE THE GENERAL PUBLIC ABOUT THE SCIENCE AND PRACTICE OF HUMAN CRYOPRESERVATION AND RELATED TOPICS, INCLUDING REJUVENATION BIOTECHNOLOGIES, MOLECULAR NANOTECHNOLOGY, LIFE EXTENSION, PREVENTATIVE HEALTH, AND RELATED RESEARCH.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $3,491,592

Program Service Revenue $2,089,486

Investment Income $145,312

Other Revenue $2,145

TOTAL REVENUE $5,728,535

Expense Breakdown

Grants Paid $0

Salaries & Benefits $1,710,136

Fundraising Expenses $120,824

Program Expenses $2,398,479

Other Expenses $2,204,762

TOTAL EXPENSES $3,914,927

Year-over-Year Comparison

	2023	2022	Change
Revenue	$5,728,535	$3,805,254	+0.5%
Expenses	$3,914,927	$3,688,494	+0.1%
Net Income	$1,813,608	$116,760	+14.5%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✓ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$520,758

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
REBECCA LIVELY	DIRECTOR	10.00	Director	$0	$0	$0
MICHAEL O'NEAL	DIRECTOR	10.00	Director	$0	$0	$0
MICHAEL SEIDL	DIRECTOR	10.00	Director	$0	$0	$0
RALPH MERKLE	DIRECTOR	10.00	Director	$0	$0	$0
ANDREW AYMELOGLU	DIRECTOR	10.00	Director	$0	$0	$0
JASON HARROW	DIRECTOR	10.00	Director	$0	$0	$0
BLAKE HONIOTES	DIRECTOR	10.00	Director	$0	$0	$0
JAMES ARROWOOD	PRESIDENT/CEO	40.00	Officer	$203,665	$18,794	$222,459
R MICHAEL PERRY	TREASURER	40.00	Officer	$42,000	$4,337	$46,337
MARJI KLIMA	CO-CEO/PRESIDENT	40.00	Officer	$176,500	$15,559	$192,059
LINDA CHAMBERLAIN	SECRETARY	40.00	Officer	$54,500	$5,403	$59,903
STEVE GRABER	DIRECTOR OF INNOVATION	40.00	Highest	$103,500	$9,695	$113,195
SHELBY CALKINS	MEDICAL RESPONSE DIRECTOR	40.00	Highest	$107,121	$13,876	$120,997
SARAH KELLY	DIRECTOR OF DEVELOPMENT	40.00	Highest	$103,008	$9,465	$112,473

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$5,728,535	$3,914,927	$30,564,278	$1,813,608
2022	$3,805,254	$3,688,494	$27,963,585	$116,760
2021	$3,943,994	$4,962,166	$25,965,160	$-1,018,172
2020	$15,560,830	$4,386,958	$24,514,498	$11,173,872
2019	$3,347,131	$4,936,084	$26,480,039	$-1,588,953
2018	$7,169,093	$15,641,107	$26,576,764	$-8,472,014